SUBSCRIBE
SUBSCRIBE

Influenza

Business people holding a meeting in a conference room
Earnings
Vir Lays Off 25% of Staff, Abandons Most Virus Work and Pivots to Cancer in Sanofi Deal
As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.
August 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Drug Development
Moderna’s COVID-Flu Combo Shot Beats Separate Vaccines in Phase III Study
Moderna’s combination vaccine candidate for COVID-19 and influenza outperformed licensed vaccines in older adults, according to late-stage results reported on Monday.
June 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Drug Development
Moderna Secures Up to $750M in Funding from Blackstone to Advance Flu Program
Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life Sciences to help advance its pipeline of flu vaccine candidates.
March 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
January 14, 2026
 · 
11 min read
Press Releases
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
January 13, 2026
 · 
10 min read
Press Releases
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
January 5, 2026
 · 
4 min read
Press Releases
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
December 22, 2025
 · 
7 min read
Press Releases
CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Vaccine Candidate
December 18, 2025
 · 
6 min read
Press Releases
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
December 18, 2025
 · 
4 min read
Press Releases
Microbix Launches New Products to Support H3N2 Flu Testing
December 10, 2025
 · 
5 min read
Press Releases
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
November 24, 2025
 · 
4 min read
Press Releases
Boehringer Ingelheim obtains two EU CVMP positive opinions for avian influenza vaccines VAXXITEK® HVT+IBD+H5 and VAXXINACT® H5
November 21, 2025
 · 
5 min read
Press Releases
Apriori Bio and A*STAR Infectious Diseases Labs Announce Strategic Partnership to Advance Next Generation Influenza Vaccines
November 18, 2025
 · 
3 min read
Press Releases
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
November 18, 2025
 · 
13 min read
Press Releases
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
November 7, 2025
 · 
5 min read
Press Releases
BlueWillow Biologics’ Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
November 6, 2025
 · 
3 min read
Press Releases
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
October 28, 2025
 · 
5 min read
Press Releases
Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025
October 22, 2025
 · 
4 min read
Press Releases
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
October 22, 2025
 · 
11 min read
Press Releases
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
October 22, 2025
 · 
7 min read
Press Releases
/C O R R E C T I O N -- Sanofi-Aventis Canada Inc./
October 21, 2025
 · 
8 min read
Press Releases
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
October 20, 2025
 · 
8 min read
Press Releases
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
October 19, 2025
 · 
5 min read
Load More